Constantine Tam

Constantine Tam

UNVERIFIED PROFILE

Are you Constantine Tam?   Register this Author

Register author
Constantine Tam

Constantine Tam

Publications by authors named "Constantine Tam"

Are you Constantine Tam?   Register this Author

100Publications

3530Reads

41Profile Views

The Addition of Low Dose Acetazolamide as an adjunct in patients undergoing High dose Methotrexate is safe and beneficial.

Intern Med J 2019 Aug 12. Epub 2019 Aug 12.

Department of Haematology, St Vincent's Hospital, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imj.14468DOI Listing
August 2019

High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.

Leuk Lymphoma 2019 Jun 11;60(6):1572-1575. Epub 2019 Jan 11.

a Department of Infectious Diseases , Peter MacCallum Cancer Centre , Parkville , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1543884DOI Listing
June 2019

Management of patients with follicular lymphoma treated first line with obinutuzumab.

Asia Pac J Clin Oncol 2019 May;15 Suppl 3:3-11

Haematology Department, Concord Hospital, University of Sydney, Concord, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13153DOI Listing
May 2019

Managing patients with ibrutinib-resistant CLL: don't stop ibrutinib until you are ready with the next therapy.

Leuk Lymphoma 2019 May 17:1-2. Epub 2019 May 17.

a Department of Haematology , St Vincent's Hospital , Melbourne , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1616189DOI Listing
May 2019

BTK/PD-1 blockade for treatment of Richter's transformation.

Lancet Haematol 2019 Feb 11;6(2):e59-e60. Epub 2019 Jan 11.

Department of Haematology, St Vincent's Hospital, Melbourne, VIC 3065, Australia; Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(18)30219-9DOI Listing
February 2019

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

N Engl J Med 2019 01 1;380(1):45-56. Epub 2018 Dec 1.

From the Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.J.S.); the Hematopoietic Cellular Therapy Program, University of Chicago Medicine, Chicago (M.R.B.); Peter MacCallum Cancer Centre, St. Vincent's Hospital and University of Melbourne, Melbourne, VIC (C.S.T.), and the Royal Prince Alfred Hospital and Department of Medicine, University of Sydney, Sydney (P.J.H.) - both in Australia; Winship Cancer Institute of Emory University, Bone Marrow and Stem Cell Transplant Center, Atlanta (E.K.W.); the Department of Hematology and Oncology, University Hospital of Cologne, Cologne (P.B.), and the Würzburg University Medical Center, Center for Allogeneic Stem Cell Transplantation, Würzburg (S.M.) - both in Germany; the Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Kansas City (J.P.M.); the Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna (U.J.); James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center, Columbus (S.J.); the Department of Hematology and Blood and Marrow Transplant, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (C.A.); the Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston (J.R.W.); Maisonneuve-Rosemont Hospital, University of Montreal, Montreal (I.F.), and the Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON (S.R.F.) - both in Canada; the Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis (V.B.); Karolinska Institutet and University Hospital, Department of Laboratory Medicine/Department of Cell Therapy and Allogeneic Stem Cell Transplantation, Stockholm (S.M.); University of Michigan Comprehensive Cancer Center, Ann Arbor (J.M.M.); the Department of Oncology, Oslo University Hospital, Oslo (H.H.); Novartis Pharma, Basel, Switzerland (S.P., O.A.); Novartis Pharmaceuticals (L.B.P., J.C.) and Novartis Institutes for BioMedical Research (R.A.), East Hanover, NJ; the Department of Hematology, Hospices Civils de Lyon, Université de Lyon, Lyon, France (G.S.); and the Center for Hematologic Malignancies, Oregon Health and Science University Knight Cancer Institute, Portland (R.T.M.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1804980
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1804980DOI Listing
January 2019

Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.

Clin Adv Hematol Oncol 2019 Jan;17(1):32-34

St Vincent's Hospital, Peter MacCallum Cancer Centre, and University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
January 2019

Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.

Leuk Lymphoma 2018 12 18;59(12):2769-2781. Epub 2018 Jun 18.

b Sir Peter MacCallum Department of Oncology , University of Melbourne , Melbourne , Victoria , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1457148DOI Listing
December 2018

Vigilance for ibrutinib-associated ventricular arrhythmias: rare but be aware.

Leuk Lymphoma 2018 12 22;59(12):2767-2768. Epub 2018 Jul 22.

b CLL Center, Dana Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1482546DOI Listing
December 2018

Comparison of gene expression and flow cytometry for immune profiling in chronic lymphocytic leukaemia.

J Immunol Methods 2018 12 26;463:97-104. Epub 2018 Sep 26.

ACRF Translational Research Laboratory, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jim.2018.09.013DOI Listing
December 2018

Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies.

Blood Rev 2018 11 23;32(6):499-507. Epub 2018 Apr 23.

Department of Infectious Diseases, Peter MacCallum Cancer Centre, Victoria, Australia; National Centre for Infections in Cancer, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia; Department of Medicine, University of Melbourne, Victoria, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0268960X173015
Publisher Site
http://dx.doi.org/10.1016/j.blre.2018.04.007DOI Listing
November 2018

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

J Clin Oncol 2018 Oct 25:JCO1800359. Epub 2018 Oct 25.

Matthew S. Davids, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Gottfried von Keudell, Yale School of Medicine, New Haven, CT; Craig A. Portell, University of Virginia Health System, Charlottesville, VA; Jonathon B. Cohen, Winship Cancer Institute of Emory University, Atlanta, GA; David C. Fisher, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Francine Foss, Yale School of Medicine, New Haven, CT; Andrew W. Roberts, Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia; John F. Seymour, Royal Melbourne Hospital, Peter MacCallum Cancer Centre, and University of Melbourne, Melbourne, Victoria, Australia; Rod A. Humerickhouse, AbbVie, Chicago, IL; and Constantine S. Tam, Royal Melbourne Hospital, Peter MacCallum Cancer Centre, St Vincent's Hospital, and University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00359
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00359DOI Listing
October 2018

Factors predicting the identification of new organisms in follow-up blood cultures drawn during episodes of neutropenic sepsis.

Br J Haematol 2018 08 23;182(3):451-453. Epub 2017 Jun 23.

Department of Microbiology, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14814DOI Listing
August 2018

Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.

Leuk Lymphoma 2018 07 13;59(7):1554-1564. Epub 2017 Sep 13.

a Department of Haematology , St Vincent's Hospital Melbourne , Fitzroy , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1375110DOI Listing
July 2018

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.

N Engl J Med 2018 Jun 1;378(25):2399-2410. Epub 2018 Jun 1.

From the National and Kapodistrian University of Athens School of Medicine, Athens (M.A.D., E.K.); ASST Grande Ospedale Metropolitano Niguarda, Milan (A.T.), and Città della Salute Hospital and University, Turin (L.O.) - both in Italy; Concord Hospital, University of Sydney, Concord, NSW (J.T.), and Peter MacCallum Cancer Centre and St. Vincent's Hospital, Melbourne, VIC (C.T.) - both in Australia; Hospital Universitario de Salamanca, Salamanca, Spain (R.G.-S.); Ottawa Hospital, University of Ottawa, Ottawa (D.M.), and Royal Victoria Hospital at McGill University Health Centre, Montreal (C.S.) - both in Canada; Département d'Hématologie, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie, Paris (V.L.), Centre Hospitalier Universitaire de Nantes, Nantes (B.M.), and Centre Hospitalier Régional Universitaire de Lille, Institute of Hematolog-Tranfusion, Lille (C.H.) - all in France; Memorial Sloan Kettering Cancer Center, New York (M.L.P.); Colorado Blood Cancer Institute, Denver (J.V.M.); Dana-Farber Cancer Institute, Boston (S.P.T.); Pharmacyclics, Sunnyvale, CA (J.L., Z.S., T.G.); and Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany (C.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1802917DOI Listing
June 2018

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

N Engl J Med 2018 03;378(13):1211-1223

From the Peter MacCallum Cancer Centre, Melbourne, VIC (C.S.T., M.A.A., R.A., S.H., R.J.H., K.B., G.T., J.D.I., M.B., D.W., S.L., S.-J.D., M.A.D., J.F.S., A.W.R.), and the Victorian Comprehensive Cancer Centre (C.S.T., M.A.A., R.A., S.H., R.J.H., K.B., D.W., S.-J.D., M.A.D., J.F.S., A.W.R.), the Faculty of Medicine (C.S.T., R.J.H., S.-J.D., M.A.D., J.F.S., A.W.R.) and Centre for Cancer Research (S.-J.D., M.A.D.), University of Melbourne, the Department of Clinical Haematology and Bone Marrow Transplantation, the Royal Melbourne Hospital (C.S.T., M.A.A., K.B., J.F.S., A.W.R.), and the Division of Cancer and Haematology, Walter and Eliza Hall Institute of Medical Research (M.A.A., A.W.R.), Parkville, VIC - all in Australia; and the University Hospital of Schleswig-Holstein, Kiel (C.P.), and Klinikum der Universität, Ludwig-Maximilian University of Munich, Munich (M.D.) - both in Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1715519DOI Listing
March 2018

Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.

Leuk Lymphoma 2017 12 15;58(12):2811-2814. Epub 2017 May 15.

a Department of Hematology , St Vincent's Hospital , Melbourne , Australia.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2017.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2017.1315115DOI Listing
December 2017

Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia.

Intern Med J 2017 Dec;47 Suppl 6:5-10

Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/imj.13680
Publisher Site
http://dx.doi.org/10.1111/imj.13680DOI Listing
December 2017

The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma.

Leuk Lymphoma 2017 11 23;58(11):2720-2723. Epub 2017 Mar 23.

a Department of Haematology , St Vincent's Hospital , Melbourne , Australia.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2017.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2017.1281414DOI Listing
November 2017

Ibrutinib may impair serological responses to influenza vaccination.

Haematologica 2017 10 28;102(10):e397-e399. Epub 2017 Jun 28.

Department of Medicine, University of Melbourne, VIC, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2017.164285DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622870PMC
October 2017

High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma.

Br J Haematol 2017 09 29;178(6):991-994. Epub 2016 Jul 29.

Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14187DOI Listing
September 2017

FDG PET in follicular lymphoma: more than a staging test?

Leuk Lymphoma 2017 07 16;58(7):1521-1523. Epub 2017 Jan 16.

a Department of Cancer Imaging , Peter MacCallum Cancer Centre , Melbourne , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1272691DOI Listing
July 2017

Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.

Intern Med J 2017 Jul;47 Suppl 4:5-10

Department of Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imj.13493DOI Listing
July 2017

Novel agents versus chemotherapy as frontline treatment of CLL.

Leuk Lymphoma 2017 06 6;58(6):1320-1324. Epub 2017 Feb 6.

a Haematology Department , St Vincent's Hospital , Fitzroy , Australia.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2017.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2017.1280606DOI Listing
June 2017

Microvesicles in chronic lymphocytic leukemia: ready for prime time in the clinic?

Leuk Lymphoma 2017 06;58(6):1281-1282

a Haematology Department , Peter MacCallum Cancer Center , Melbourne , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1298756DOI Listing
June 2017

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.

Blood 2017 06 4;129(25):3362-3370. Epub 2017 May 4.

Department of Clinical Haematology and Bone Marrow Transplantation, The Royal Melbourne Hospital, Parkville, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-01-763003DOI Listing
June 2017

Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors.

Br J Haematol 2017 04 15;177(2):324-328. Epub 2016 May 15.

Department of Haematology, Peter MacCallum Cancer Centre, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14062DOI Listing
April 2017

Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.

Br J Haematol 2017 03 25;176(5):829-831. Epub 2016 Feb 25.

Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14000DOI Listing
March 2017

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Lancet Oncol 2017 Feb 13;18(2):230-240. Epub 2017 Jan 13.

Victorian Comprehensive Cancer Centre, Parkville, Melbourne, VIC, Australia; Faculty of Medicine, University of Melbourne, Parkville, Melbourne, VIC, Australia; Department of Clinical Haematology and BMT, The Royal Melbourne Hospital, Parkville, Melbourne, VIC, Australia; Division of Cancer and Haematology, The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30012-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316338PMC
February 2017

Central nervous system immune reconstitution inflammatory syndrome after ibrutinib therapy for Richter transformation.

Leuk Lymphoma 2017 01 21;58(1):207-210. Epub 2016 Jun 21.

a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Australia.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2016.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2016.1179298DOI Listing
January 2017

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.

Br J Haematol 2016 Nov 9;175(3):462-466. Epub 2016 Sep 9.

Service d'Hématologie Biologique, GHUPSSD, AP-HP, U978 INSERM, Université Paris 13, Sorbonne Paris Cité, Labex Inflamex, Bobigny, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14324DOI Listing
November 2016

A novel way to consolidate incomplete responses in chronic lymphocytic leukemia/small lymphocytic lymphoma.

Leuk Lymphoma 2016 15;57(3):503-4. Epub 2015 Oct 15.

c Department of Hematology , Hadassah University Hospital and Hebrew University Medical School , Jerusalem , Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1096358DOI Listing
August 2016

Defining the appropriate starting dose of lenalidomide in chronic lymphocytic leukemia: remember the old fable of the hare and the tortoise.

Leuk Lymphoma 2016 17;57(6):1247-8. Epub 2016 Feb 17.

c Department of Hematology , Hadassah University Hospital and Hebrew University Medical School , Jerusalem , Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1137294DOI Listing
August 2016

Maintenance therapy in CLL: resolving the controversy.

Lancet Haematol 2016 Jul 16;3(7):e304-5. Epub 2016 Jun 16.

Haematology Department, St Vincent's Hospital, Fitzroy, VIC, Australia; Haematology Department, Peter MacCallum Cancer Center, East Melbourne, VIC, Australia; University of Melbourne, Parkville, VIC, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(16)30046-1DOI Listing
July 2016

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

Blood 2016 06 11;127(25):3215-24. Epub 2016 Apr 11.

Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia; Department of Clinical Hematology and Bone Marrow Transplantation, The Royal Melbourne Hospital, Parkville, VIC, Australia;

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2016-01-68
Publisher Site
http://dx.doi.org/10.1182/blood-2016-01-688796DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920022PMC
June 2016

Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.

Semin Oncol 2016 Apr 6;43(2):274-9. Epub 2016 Feb 6.

University of Melbourne, Parkville, Victoria, Australia; Department of Clinical Haematology and BMT, Royal Melbourne Hospital, Parkville, Victoria, Australia; Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2016.02.014DOI Listing
April 2016

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

N Engl J Med 2015 Dec 6;373(25):2425-37. Epub 2015 Dec 6.

From the University of Texas MD Anderson Cancer Center, Houston (J.A.B.); Azienda Ospedaliera Niguarda Cà Granda (A.T.) and Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele (P.G.), Milan, and the Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara (G.G.) - all in Italy; Wilmot Cancer Institute, University of Rochester, Rochester, NY (P.M.B.); Medical University of Lodz and Copernicus Memorial Hospital, Lodz (T.R.), the Department of Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice (S.G.), and the Department of Hematology, University Clinical Center of Medical University of Gdansk, Gdansk (A.H.) - all in Poland; Tom Baker Cancer Centre, Calgary, AB, Canada (C.O.); Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv (O.B.), and Hadassah University Hospital, Hebrew University Medical School, Jerusalem (A.P.) - both in Israel; Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds (P.H.), Kings College Hospital, London (S.D.), Royal Bournemouth Hospital, Bournemouth (H.M.), and University of Oxford, Oxford (A.S.) - all in the United Kingdom; Washington University School of Medicine, St. Louis (N.L.B.); Jiangsu Province Hospital, Nanjing, China (J.L.); North Shore Hospital, Auckland, New Zealand (D. Simpson); Stanford University School of Medicine, Stanford (S.C.), City of Hope National Medical Center, Duarte (T.S.), Pharmacyclics, Sunnyvale (D. Suri, M.C., F.C., L.S., D.F.J.), and Moores Cancer Center, University of California, San Diego, San Diego (T.J.K.) - all in California; St. Vincent's Hospital, University of Melbourne (H.Q.), and Peter MacCallum Cancer Centre and St. Vincent's Hospital (C.S.T.), Melbourne, VIC, Australia; Institute of Blood Pathology and Transfusion Medicine, National Academy of Medical Sciences of Ukraine, Lviv, Ukraine (Z.M.); Norton Cancer Institute, Louisville, KY (D.A.S.);

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1509388DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722809PMC
December 2015

Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Future Oncol 2015 ;11(5):719-33

University of New Mexico Cancer Center, 1201 Camino de Salud NE, Albuquerque, NM 87131, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.14.272DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920055PMC
November 2015

How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?

Leuk Lymphoma 2015 Jun 20;56(6):1599-610. Epub 2014 Nov 20.

Department of Haematology, Derriford Hospital , Plymouth , UK.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.3109/10428194.2014.96
Publisher Site
http://dx.doi.org/10.3109/10428194.2014.963083DOI Listing
June 2015

Association between early peak temperature and mortality in neutropenic sepsis.

Ann Hematol 2015 May 18;94(5):857-64. Epub 2014 Dec 18.

Wellington Blood & Cancer Centre, Capital & Coast District Health Board, Wellington, New Zealand,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-014-2273-zDOI Listing
May 2015

Src family kinases and their role in hematological malignancies.

Leuk Lymphoma 2015 Mar 21;56(3):577-86. Epub 2015 Jan 21.

Haematology Department and Victorian Cancer Cytogenetics Service, St Vincent's Hospital , Fitzroy , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.907897DOI Listing
March 2015

How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?

Leuk Lymphoma 2015 Mar 17;56(3):587-93. Epub 2015 Feb 17.

Haematology Department, Peter MacCallum Cancer Center , East Melbourne, Victoria , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1011641DOI Listing
March 2015

The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia.

Br J Haematol 2015 Feb 1;168(4):576-82. Epub 2014 Oct 1.

Centre for Cancer Research, MIMR-PHI Institute of Medical Research, Clayton, Vic., Australia; Centre for Inflammatory Diseases, Monash University, Clayton, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13151DOI Listing
February 2015

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.

Blood 2015 Feb 17;125(6):915-23. Epub 2014 Dec 17.

Department of Haematology, and Discipline of Medicine, School of Medicine, University of Adelaide, Adelaide, Australia; Australasian Leukemia and Lymphoma Group, Melbourne, Australia; Cancer Theme, South Australia Health and Medical Research Institute, Adelaide, Australia;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-07-590315DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161008PMC
February 2015

Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy.

Blood 2015 Jan 21;125(1):71-81. Epub 2014 Oct 21.

Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-07-588236DOI Listing
January 2015

Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.

Blood 2014 Dec 10;124(26):3991-5. Epub 2014 Oct 10.

INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-06-583294DOI Listing
December 2014

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

Blood 2014 Dec;124(25):3829-30

Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-10-604272DOI Listing
December 2014

B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21.

Int Immunol 2014 Jul 4;26(7):383-95. Epub 2014 Feb 4.

Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg - Hessen and Institute of Transfusion Medicine,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/intimm/dxu001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133571PMC
July 2014

A new prognostic score for CLL.

Blood 2014 Jul;124(1):1-2

PETER MACCALLUM CANCER CENTRE; UNIVERSITY OF MELBOURNE.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2014-05-57
Publisher Site
http://dx.doi.org/10.1182/blood-2014-05-575407DOI Listing
July 2014

Venous thromboembolism prevention in patients undergoing colorectal surgery for cancer.

ANZ J Surg 2014 Apr 19;84(4):284-8. Epub 2013 Jun 19.

General Internal Medicine Department, St Vincent's Hospital, Fitzroy, Victoria, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ans.12296
Publisher Site
http://dx.doi.org/10.1111/ans.12296DOI Listing
April 2014

Effective treatment of Waldenström macroglobulinemia associated pure red cell aplasia with standard antilymphomatous chemotherapy.

Leuk Lymphoma 2014 Mar 28;55(3):692-4. Epub 2013 Aug 28.

Department of Haematology, St Vincent's Hospital , Melbourne , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.802316DOI Listing
March 2014

CD38 expression in CLL: a dynamic marker of prognosis.

Leuk Lymphoma 2014 Jan 7;55(1):1-2. Epub 2013 May 7.

Department of Clinical Haematology and Bone Marrow Transplantation, Royal Melbourne Hospital , Parkville, Victoria , Australia.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.3109/10428194.2013.78
Publisher Site
http://dx.doi.org/10.3109/10428194.2013.789510DOI Listing
January 2014

High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?

Leuk Lymphoma 2013 Dec 21;54(12):2575-6. Epub 2013 May 21.

Division of Cancer Medicine, Peter MacCallum Cancer Centre , Melbourne, Victoria , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.796059DOI Listing
December 2013

Protein kinase C isoform expression in chronic lymphocytic leukemia: a potential target for therapy?

Leuk Lymphoma 2013 Oct 19;54(10):2098-9. Epub 2013 Apr 19.

Northern Blood Research Centre, Kolling Institute of Medical Research, Royal North Shore Hospital , NSW , Australia.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.3109/10428194.2013.77
Publisher Site
http://dx.doi.org/10.3109/10428194.2013.779692DOI Listing
October 2013

Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.

Neuro Oncol 2013 Aug 15;15(8):1068-73. Epub 2013 Mar 15.

Inter-hospital Multi-institution Project Alliance and Collaboration Taskforce, Monash Medical Centre, Clayton, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/not032DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714147PMC
August 2013

Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.

Eur J Haematol 2013 Aug 15;91(2):157-63. Epub 2013 Jun 15.

Department of Infectious Diseases and Infection Control, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12135DOI Listing
August 2013

Investigational Janus kinase inhibitors.

Expert Opin Investig Drugs 2013 Jun 23;22(6):687-99. Epub 2013 Feb 23.

Peter MacCallum Cancer Center, Department of Hematology, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2013.774373DOI Listing
June 2013